Skip to main content

Table 4 Effect of simvastatin in CHD patients with MMP-9 rs3918242 polymorphism

From: Impact of matrix metalloproteinase 9 rs3918242 genetic variant on lipid-lowering efficacy of simvastatin therapy in Chinese patients with coronary heart disease

  week CC (n = 188) CT (n = 69) TT (n = 7)
Mean ± SD % Change Mean ± SD % Change Mean ± SD % Change
TG (mmol/L) 0 1.52 ± 0.19 28.13 ± 3. 1.73 ± 0.25 28.19 ± 3.0 1.87 ± 0.27* 28.12 ± 3.22
12 1.11 ± 0.21 29 1.21 ± 0.18 7 1.39 ± 0.23  
TC (mmol/L) 0 5.15 ± 0.61 18.24 ± 2. 5.11 ± 0.59 18.59 ± 3.0 5.12 ± 0.51 18.71 ± 3.26
12 4.34 ± 0.47 67 4.36 ± 0.49 6 4.37 ± 0.56  
HDL-C (mmol/L) 0 1.10 ± 0.19 15.23 ± 2. 1.09 ± 0.18 14.87 ± 2.6 1.13 ± 0.21 15.61 ± 2.42
12 1.29 ± 0.23 54 1.29 ± 0.22 1 1.29 ± 0.22
LDL-C (mmol/L) 0 3.09 ± 0.26 24.23 ± 5. 3.13 ± 0.28 27.50 ± 4.4 3.38 ± 0.37* 34.53 ± 4.0
12 2.35 ± 0.32 78 2.27 ± 0.24 4 2.10 ± 0.26* 0*
VLDL-C (mmol/L) 0 1.04 ± 0.16 34.16 ± 4. 1.01 ± 0.19 34.89 ± 4.5 1.08 ± 0.23 35.14 ± 4.6
12 0.79 ± 0.09 31 0.75 ± 0.11 7 0.81 ± 0.13 9
MMP-9 (ng/ml) 0 76.28 ± 21.26 24.38 ± 6.59 82.28 ± 21.26 23.10 ± 9.27 88.28 ± 22.47 22.37 ± 7.82
12 58.75 ± 20.21   63.75 ± 20.21   68.75 ± 20.21  
TNF-α (pg/ml) 0 134.73 ± 51.38 26.48 ± 4.11 137.08 ± 55.63 25.07 ± 5.12 135.98 ± 60.12 24.46 ± 2.99
12 100.26 ± 49.34   106.65 ± 50.04   99.65 ± 43.87  
IL-10 (pg/ml) 0 100.13 ± 36.17 47.33 ± 9.28 95.08 ± 34.79 52.04 ± 11.62 103.35 ± 40.14 48.27 ± 10.56
12 51.28 ± 26.21   47.29 ± 29.06   53.91 ± 22.38  
  1. Values are expressed as mean ± SD. *P <0.0001 compared with the CC genotype by one-way ANOVA followed with Bonferroni post-hoc test for pair-wise comparison. § P <0.0001 compared with before treatment by paired student’s t-Test. HD coronary heart disease, MMP-9 matrix metalloproteinase-9, TC total cholesterol, TG triglyceride, HDL-C high density lipoprotein cholesterol, LDL-C low density lipoprotein cholesterol, VLDL-C very low density lipoprotein cholesterol